Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year Low – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week low during trading on Wednesday . The stock traded as low as $10.88 and last traded at $10.91, with a volume of 377079 shares traded. The stock had previously closed at $11.40.

Analyst Ratings Changes

DYN has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. JPMorgan Chase & Co. cut their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Trading Down 3.0 %

The stock has a 50 day simple moving average of $13.33 and a 200-day simple moving average of $23.66. The firm has a market capitalization of $1.30 billion, a P/E ratio of -3.22 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 6,237 shares of company stock valued at $77,760. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the third quarter worth $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the third quarter worth about $36,000. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics in the 4th quarter worth about $50,000. KBC Group NV lifted its holdings in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares in the last quarter. Finally, Quest Partners LLC boosted its position in Dyne Therapeutics by 898.3% in the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock valued at $123,000 after buying an additional 3,090 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.